Ticker archive · $SUPN

$SUPN Filing Signals & Market Reactions

Delayed, SEO-crawlable recaps of AI-scored catalysts for $SUPN — including observed post-filing price moves. Live streaming stays exclusive to VIP.

? All delayed signals

$SUPN

$SUPN – Supernus Reports Q3 Revenues of $226.8M (+18% YoY) and Diluted EPS of $0.35

SUPERNUS PHARMACEUTICALS, INC.

2026-10-29 00:00:00 UTC · SEC_8K · All $SUPN

?? Positive AI Sentiment (+6.5 / 10)

Total revenues rose 18% YoY to a record $226.8 million in Q3 2026.
Operating turnaround with net income reaching $20.9 million compared to a $(45.1) million net loss in Q3 2025.
Diluted EPS improved to $0.35 from $(0.80) in the prior-year period.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?

$SUPN

$SUPN – Supernus Terminates UBS Credit Line Ahead of Indivior Merger Completion

SUPERNUS PHARMACEUTICALS, INC.

2026-10-26 00:00:00 UTC · SEC_8K · All $SUPN

? Neutral AI Sentiment (+0.5 / 10)

Terminated uncommitted demand revolving credit line with UBS Bank USA.
Action taken ahead of closing the previously announced business combination with Indivior Pharmaceuticals.
Prepares for a new senior secured credit facility for the combined entity.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?